Cover Image
市場調查報告書

Pol蛋白:開發中產品分析

Pol Polyprotein - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 365779
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
Pol蛋白:開發中產品分析 Pol Polyprotein - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 53 Pages
簡介

本報告提供以Pol蛋白為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Pol蛋白 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • GeoVax Labs, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0646TDB

Summary

Global Markets Direct's, 'Pol Polyprotein - Pipeline Review, H2 2016', provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
  • The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects
  • The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Pol Polyprotein
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Pol Polyprotein Overview 6
  • Therapeutics Development 7
  • Pol Polyprotein - Products under Development by Stage of Development 7
  • Pol Polyprotein - Products under Development by Therapy Area 8
  • Pol Polyprotein - Products under Development by Indication 9
  • Pol Polyprotein - Pipeline Products Glance 10
  • Late Stage Products 10
  • Early Stage Products 11
  • Pol Polyprotein - Products under Development by Companies 12
  • Pol Polyprotein - Products under Development by Universities/Institutes 14
  • Pol Polyprotein - Therapeutics Assessment 16
  • Assessment by Monotherapy/Combination Products 16
  • Assessment by Route of Administration 17
  • Assessment by Molecule Type 19
  • Pol Polyprotein - Companies Involved in Therapeutics Development 21
  • GeoVax Labs, Inc. 21
  • Inovio Pharmaceuticals, Inc. 22
  • Johnson & Johnson 23
  • Pol Polyprotein - Drug Profiles 24
  • GOVXB-11 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • GOVXC-11 - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • GOVXC-21 - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • HIV [serotype Ad26] (tetravalent) vaccine - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • HIV-1 (bivalent) vaccine - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • HIV-1 vaccine 11 - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • HIV-1 vaccine 5 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • MVATG-17401 - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • PENNVAX-B - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • PENNVAX-GP - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • Pol Polyprotein - Dormant Projects 40
  • Pol Polyprotein - Featured News & Press Releases 41
  • Oct 20, 2016: GeoVax HIV Vaccine Clinical Data Presented at HIVR4P Conference 41
  • Aug 02, 2016: GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials 41
  • Jul 14, 2016: Inovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV 42
  • Jun 30, 2016: GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial 43
  • May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 43
  • Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant 44
  • Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates 45
  • Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine 45
  • Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine 46
  • Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress 47
  • Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program 48
  • Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases 49
  • Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV 49
  • Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data 50
  • Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health 51
  • Appendix 52
  • Methodology 52
  • Coverage 52
  • Secondary Research 52
  • Primary Research 52
  • Expert Panel Validation 52
  • Contact Us 52
  • Disclaimer 53

List of Tables

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Therapy Area, H2 2016 8
  • Number of Products under Development by Indication, H2 2016 9
  • Comparative Analysis by Late Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Number of Products under Development by Companies, H2 2016 12
  • Products under Development by Companies, H2 2016 13
  • Number of Products under Investigation by Universities/Institutes, H2 2016 14
  • Products under Investigation by Universities/Institutes, H2 2016 15
  • Assessment by Monotherapy/Combination Products, H2 2016 16
  • Number of Products by Stage and Route of Administration, H2 2016 18
  • Number of Products by Stage and Molecule Type, H2 2016 20
  • Pipeline by GeoVax Labs, Inc., H2 2016 21
  • Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 22
  • Pipeline by Johnson & Johnson, H2 2016 23
  • Dormant Projects, H2 2016 40

List of Figures

  • Number of Products under Development for, H2 2016 7
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Assessment by Monotherapy/Combination Products, H2 2016 16
  • Number of Products by Routes of Administration, H2 2016 17
  • Number of Products by Stage and Routes of Administration, H2 2016 17
  • Number of Products by Molecule Types, H2 2016 19
  • Number of Products by Stage and Molecule Type, H2 2016 19
Back to Top